Of course, we will have to keep a close eye on the development of the pipeline and its diversification with the studies conducted on promising new treatment candidates and the various results of clinical trials in different phases. Of particular note here are the trials conducted on the group's flagship products such as Filgotinib for the treatment of rheumatoid arthritis or Crohn's disease and GLPG1205, which targets inflammatory diseases of the small intestine in general.
During the last five years, and despite the fact that this Dutch company has not paid any dividend to its shareholders, we can observe a good performance of this stock on the stock exchange. In fact, the five-year performance of this stock has reached a total increase of 508.59%. In the last year alone, i.e. 2019, the stock has also achieved a major performance with +96.68%.